A Foundation-Funded Project

SARAWAK HEART FOUNDATION FUNDS GENETIC TESTING FOR INHERITED CARDIOVASCULAR DISEASE

3 January 2024 – Sarawak Heart Foundation has contributed RM100,000 towards a fund for genetic testing for  inherited cardiovascular disease at Sarawak Heart Centre.  

The fund was set up in 2021 with RM50,000 from the Foundation, and has benefitted 58 patients, including 8 children. Last year, the genetic testing service was extended to children  with inherited cardiovascular disease (mainly inherited aortopathies). These children are  under the careful care of the paediatric cardiology team at Sarawak Heart Centre. With  another contribution of RM50,000 from the Foundation last month, the Centre will be able to  support more children. 

Consultant cardiologist Dr Oon Yen Yee who initiated the fund, said that the purpose of this  fund is to subsidize or sponsor patients from the lower income group so that genetic testing  is accessible to all. Inherited cardiovascular disease is one that has been passed on through  families. Many cardiac diseases can be inherited, including cardiomyopathy, high cholesterol,  arrhythmias and congenital heart disease. They can affect people of any age. 

Dr Oon explained that symptoms reported by patients with inherited cardiovascular include  palpitations, fainting spells, shortness of breath and chest pain. Some patients do not display  any symptoms, and some may have risk of sudden cardiac death. Contrary to many people’s  beliefs, inherited cardiovascular diseases are not uncommon. In Sarawak Heart Centre, the  most common inherited cardiovascular disease seen is hypertrophic cardiomyopathy (HCM).  HCM is a disease affecting the heart muscle, causing it to thicken abnormally.  

“Many patients with HCM under our care, are healthy individuals who display no symptoms.  They are usually referred to Sarawak Heart Centre because of abnormal heart findings from  a health check.” 

“Genetic testing can help to confirm the diagnosis of an inherited cardiovascular disease. It  can also help to alleviate unnecessary anxiety among family members, because through  genetic screening, those who do not carry the gene will not have the disease.” 

“However, not all patients with inherited cardiovascular disease will have a positive genetic  test or a pathogenic mutation identified. There are patients where genetic testing only picks  up a gene variant that is of “uncertain significance”. Some may even have a negative test. This  is because the current scientific data is insufficient to classify the gene variant as a disease causing variant, or the gene causing the disease has not been identified. It does not mean  that the patients do not have the disease, and the family screening approach in this group of  patients will be different from the group of patients with a pathogenic mutation identified.” 

Genetic testing has also allowed the doctors to provide individualized and targeted treatment  for patients with inherited cardiovascular disease. Dr Oon cited a case of a patient with heart  failure due to Titin gene mutation. His mother also suffers from heart failure and has passed  down the gene to the patient. Because Titin mutation carries a better prognosis compared to  other form of cardiomyopathy, the patient was offered cardiac contractility modulation (CCM)  

therapy. CCM is a relatively new device-based therapy for patients with heart failure. The treatment can help improve heart function. He became the first patient to receive CCM  therapy in South-east Asia, and is now recovering and doing well.  

The genetic tests at Sarawak Heart Centre are sent to a US-based company called INVITAE. The current cost of a genetic test is USD 349 per test. Including transportation fees which  ranges from RM 150 to RM 200, a patient would need to pay up to RM 1900 for a genetic test. When a pathogenic mutation is detected in a patient, the company provides free testing to  immediate family members, regardless of numbers.  

Last year, Sarawak Heart Centre has started cardiogenetic clinic service, making it the first cardiac centre in the Ministry of Health of Malaysia to establish cardiogenetic clinic. The clinic is helped run by qualified geneticists from General Hospital Kuala Lumpur. The clinic session  provides comprehensive cardiovascular evaluations, genetic counselling, genetic testing and  individualized treatment plans for patients with, or at risk for inherited cardiovascular disease. 

Dr Oon shares that patients often ask “Will a genetic test change the treatment of our heart disease?”.  

“Unfortunately, there is currently no cure for most of the inherited cardiovascular diseases.  The treatment provided is mainly for symptom alleviation and prevention of sudden cardiac  death. But there are studies examining treatment targeted at the mutated gene, and the  findings showed promising results. In the future, these investigational treatments called gene  therapy might offer a complete cure for inherited cardiovascular disease.” 

Dr Oon also brought up the social implications when a person is tested positive for an  inherited cardiovascular disease. Those who are professional athletes will be advised to stop  participating in competitive sports, hence affecting their career and income. Insurance  companies may impose certain restrictions or limit on their coverage. And the fear of passing  down the gene to their offspring may hinder one from having a child.  

“That is why we provide counselling before genetic testing, and when the results are out,  another session of counselling will be arranged to explain the test results and the next course  of action. We will try our best to help you and your family, so allow us to explain genetic  testing to you when it is indicated. There may be no cure for the heart problem at present,  but in the future, things might change”, she said. 

Second cardiogentic clinic on 9 November 2023. From right to left: Dr. Ling Hwei Sung (heart  failure specialist), Dr. Joshua Chung (cardiologist), Dr.Ngu Lai Hock (Head of Clinical Genetic  Malaysia), Dr. Oon Yen Yee (cardiologist), and Dr. Nadia binti Mohammad Nazri (medical  officer).
First cardiac contractility modulation (CCM) therapy implantation in South East Asia on 5  December 2022 for a patient with dilated cardiomyopathy due to Titin gene mutation.